Catalent, Inc. (NYSE:CTLT) Given Average Rating of “Hold” by Analysts

Catalent, Inc. (NYSE:CTLT) has earned a consensus rating of “Hold” from the thirteen analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $52.46.

A number of equities research analysts have commented on CTLT shares. Barclays increased their price objective on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. UBS Group reaffirmed a “neutral” rating and issued a $63.50 target price (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. StockNews.com began coverage on shares of Catalent in a research note on Tuesday. They set a “sell” rating on the stock. Stephens reissued an “equal weight” rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 6th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th.

Catalent Price Performance

NYSE CTLT opened at $56.26 on Wednesday. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34. The company has a fifty day simple moving average of $55.53 and a 200 day simple moving average of $47.07. The company has a market cap of $10.17 billion, a P/E ratio of -8.27, a P/E/G ratio of 3.53 and a beta of 1.20. Catalent has a 1 year low of $31.45 and a 1 year high of $68.81.

Catalent (NYSE:CTLT) last released its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. Catalent’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.62 earnings per share. On average, sell-side analysts predict that Catalent will post 0.48 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CTLT. KB Financial Partners LLC bought a new position in Catalent in the 1st quarter valued at approximately $30,000. Covestor Ltd increased its position in Catalent by 84.9% during the 1st quarter. Covestor Ltd now owns 562 shares of the company’s stock valued at $62,000 after purchasing an additional 258 shares during the period. Gladius Capital Management LP acquired a new stake in Catalent during the 3rd quarter valued at approximately $28,000. Exchange Traded Concepts LLC acquired a new stake in Catalent during the 3rd quarter valued at approximately $31,000. Finally, GAMMA Investing LLC acquired a new stake in Catalent during the 4th quarter valued at approximately $33,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.